Adventris Pharmaceuticals

NCT00194740

Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer

NCT00003257

Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer

NCT00206505

Neoadjuvant Taxotere

NCT00148070

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

NCT00005800

Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer

NCT00220064

A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI Tumours

NCT00196651

HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection

NCT00193245

Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

NCT00193037

Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

NCT00183924

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

NCT00193089

Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer

NCT00165464

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

NCT00193323

Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients

NCT00193024

Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

NCT01652820

Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer

NCT00193050

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

NCT00318903

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

NCT00151073

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

NCT00191490

A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

NCT00048087

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

NCT00214058

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

NCT00183794

Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma

NCT00198237

Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer

NCT00238615

Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

NCT00068341

Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer

NCT00186420

Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation

NCT00090610

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

NCT00193284

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

NCT00118131

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00215930

The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer

NCT00193115

Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer

NCT00257348

Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

NCT00193427

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

NCT00087035

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

NCT00193232

Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

NCT00280735

Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

NCT00210184

Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer

NCT00193271

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

NCT00121758

AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers

NCT00118053

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

NCT00177255

A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers

NCT00193180

Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer

NCT00216008

Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

NCT00268593

Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer

NCT00232479

Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer

NCT00270894

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

NCT00426127

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

NCT03004001

Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome